Feb 27, 2025 · 42m · catalyst
Cultivated meat’s “trough of disillusionment”
0:00 / 0:00
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
Host Shail Khan and New Harvest executive director Isha Datar analyze why the cellular agriculture industry entered the hype cycle's 'trough of disillusionment' and discuss the technical, economic, and open-science innovations necessary to achieve commercial viability.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Shayle holds 24.1% of the talking time here. How this is scored →
Shayle as informed peer 3.2 Guest teaching 3.2 Guest disagreement 1.3 Shayle pushing back 1.2
speaking balance: gold is Shayle, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 38:18 Pushing back on painting a purely optimistic outlook
Isha jokingly yet pointedly challenges Shayle's premise when asked to provide an exclusively rosy forecast, noting she feels guided in a specific direction before giving a nuanced realistic perspective.
Hardest push from Shayle ▶ 22:45 Probing the core cost disparity per kilogramShayle presses on the structural economic reality that biopharma tools operate with radically higher value per kilogram than commodity chicken breast, demanding a clear framework for viable price parity.
Biggest teaching moment ▶ 10:40 Educating on the lack of standardized cell toolsIsha educates Shayle on the basic biology gap, contrasting well-characterized biomedical cell lines like CHO cells with cell ag researchers having to source raw tissue from abattoirs.
Shayle holds their own ▶ 12:36 Drawing structural parallels to engineered carbon removalShayle brings his venture capital domain expertise into the technical discussion, comparing cellular agriculture's premature commercialization directly to fundamental science lags in engineered carbon dioxide removal.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | Shayle as informed peer | Guest teaching | Guest disagreement | Shayle pushing back | Why |
|---|---|---|---|---|---|---|
| Announcement of the Open Circuit Roundtable Podcast | 0 | 0 | 0 | 0 | Introductory announcements, show credits, and sponsor midrolls. No direct dialogue or host-guest power dynamics occur. | |
| Introduction to Cellular Agriculture and Guest Isha Datar | 2 | 3 | 1 | 1 | Shayle opens by explicitly stating his beginner mindset, framing the episode as Cellular Agriculture 101. Isha immediately reframes terminology by explaining why she prefers cellular agriculture over meat. | |
| The Historical Evolution of Cellular Agriculture Companies | 3 | 4 | 1 | 1 | Shayle asks for a historical retrospective on why initial commercial expectations underperformed. Isha outlines the 10-year arc from vertically integrated animal mimicry to picks-and-shovels supply chain companies. | |
| Upstream Technical Challenges and Structural Academic Divides | 6 | 5 | 2 | 2 | Isha identifies structural academic silos between biomedical funding and agriculture colleges as an upstream barrier. Shayle connects this to parallels in engineered carbon dioxide removal where venture capital rushed in before fundamental research foundations were built. | |
| Analyzing Biopharma Cost Paradigms and Food Realities | 5 | 4 | 2 | 2 | Shayle articulates the cost differential between high-margin biopharma therapeutics and low-margin commodity protein per kilogram. Isha agrees with the disparity but challenges biopharma's lack of cost-down incentive. | |
| Midroll Advertisements for Bloom Energy, Engie, and Energy Hub | 0 | 0 | 0 | 0 | Midroll advertising break for Bloom Energy, Engie, and Energy Hub. | |
| Scaling CapEx, Downstream Processing, and Realistic Economics | 4 | 5 | 2 | 2 | Isha breaks down the CapEx and OpEx cost stack, arguing against relying on strict biopharma models like David Humbird's techno-economic analysis. She uses a high-cost laboratory chocolate chip cookie analogy to illustrate current input pricing. | |
| Open Innovation: Shared Facilities, Cell Banks, and Regulation | 4 | 4 | 1 | 1 | Isha explains the necessity of open-access pilot facilities and standardized cell lines to prevent duplicated capital expenditure. She also clarifies that recent regulatory approvals often serve as investor signaling rather than imminent commercial mass deployment. | |
| Strategic Niches: High-Value Products and Alternative Applications | 5 | 3 | 1 | 1 | Shayle asks whether entering through luxury high-value niches matches the Tesla playbook. Isha agrees and adds technical nuance regarding why liver pate and uncooked sashimi bypass current structural texturing and cooking transformation barriers. | |
| Five-Year Industry Outlook and the Role of Collaboration | 3 | 4 | 3 | 2 | When Shayle asks for an optimistic five-year picture, Isha jokingly pushes back against being forced into pure optimism before arguing that a deeper trough may force essential industry collaboration and a pivot to precision fermentation ingredients. |
Statements from this episode (17)
Datar: 'Cellular Agriculture' Is Preferable Because Meat Is Not a Sector
“Well, my favorite term is cellular agriculture because I don't think meat is a sector.”
Datar: Cultivated meat startups shouldn't attempt full vertical integration early on
“If we actually think about a world where food is grown from cells, we need a really robust, diverse kind of economy behind it with many different players and so on. We can't just come out of the gate vertically integrated like the meat industry today.”
Datar: Cultivated meat is in the 'trough of disillusionment' but will happen
“We're in this kind of trough of disillusionment, as they call it in the hype cycle terminology, where people are like, what do you mean this thing will never happen, it's been way too long, when actually, it will happen, it's just, now we've kind of set oursel…”
Datar: Cellular agriculture lacks standardized cell lines common in biomedicine
“We don't have those standardized cells in cellular agriculture. So where one researcher in the biomedical space can just open up a catalog and say, hey, I need to order this, and this, You understand how they perform, and you just get to work on your work. The…”
Datar: Venture capital is improperly subsidizing basic research in emerging tech
“It's a lot easier to be a private company raising VC money to do research, which is ultimately should just be basic research, because the stuff that's going to be competitive and on the market probably can't happen until that first research happens.”
Datar: Biopharma lacks incentives to lower costs, but cell ag must
“Biopharma has set this precedent that this is what the price of things should be, and they have no incentive to bring the prices down. Cellular agriculture does have an incentive to bring the price down, and it must bring the price down.”
Datar: Cultivated meat factories should resemble food processing, not biopharma
“But I also think if we're willing to have that same disruptive paradigm shifting mentality, that maybe the manufacturer of this looks more like vitamin or food processing or those kind of other still factories, still produce stuff that you consume, but isn't t…”
Datar: Climate change and avian flu will destabilize chicken prices
“The price of chicken is not as stable as we think it's going to be, especially in a climate changed world. We're seeing that with the price of eggs right now, with the avian flus. And so, you know, let's, let's not forget that things that seem constant for the…”
Datar: Growth media is the largest ongoing cost in cultivated meat
“The media that you're feeding the cells is probably going to be the thing that costs the most. Same, same like with animals. It's like the feed that's the biggest contributor to the cost of a cow.”
Datar: Commercial cultivated meat manufacturing requires hundreds of millions in CapEx
“I would say tens of millions of dollars could make something that's really great right now that would be useful for the whole field. Hundreds of millions, we'd start getting into more, like, manufacturing, you know, in a, like, way that is more than, like, a c…”
Datar: Lack of shared facilities in cultivated meat causes redundant capital waste
“What's happening now is the companies are all building their own separate facilities. There's no standardization. If one works, great. If one doesn't work, like, no one would know why it doesn't work, and then it doesn't prevent the next person from spending t…”
Datar: Cell ag growth media startups can pivot to selling to pharma
“Even though that's a big cost center, that is actually kind of like a good place for business right now, because you can sell better media, cheaper media ingredients to pharma today.”
Datar: Cultivated meat regulatory approvals are investor milestones, not commercial rollouts
“I don't always know if the approvals are like the most significant thing. Like to me, they kind of read like a investor milestone more than a, oh, this is just like the last stop before we blow our product up on the market kind of thing.”
Datar: Cultivated sashimi avoids cooking unpredictability inherent to cultivated meat
“There's a big scientific process, like food science transformation that happens when you cook something. And cultivated meat, you don't know exactly how it might perform in a pan. You hope it's going to be exactly the same as the cells from an animal, but you …”
Datar: Cellular agriculture research has boomed significantly since 2015
“There's institutes of cellular agriculture around the world, where in 2015 there was zero. There are hundreds of grad students working on cell ag research around the world, where in 2015 there was like two, you know, like I could count them on one hand.”
Datar: Cultivated meat may fail while lab-grown milk and eggs succeed
“Cellular agriculture as a concept is so much bigger than meat, and it's very possible that things like milk proteins or egg proteins or just ingredients in our food Are actually going to make a bigger difference for the climate and for nutrition and food and a…”
Datar: Less marketing distraction will yield better cell ag science over time
“I also think in the next five years, better science will happen because the distraction of marketing and comms is decreasing, and so all these little kind of news tidbits about what's going on that really, you know, they sound big when they come out, but did t…”